Friday, February 13, 2026 at 2:03 PM
Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% revenue growth in 2026 following the launch of its next-generation Covid vaccine.
Humana reported a wider fourth-quarter loss as medical costs continue to rise and said it expects a sharp decline in 2026 earnings due to lower quality ratings of its Medicare plans.
CEO Pascal Soriot said in a call with reporters on Tuesday that the group’s confidence in reaching $80 billion in revenue in 2030 was growing.
Belen Garijo will succeed Paul Hudson as CEO following a string of clinical setbacks at the drugmaker.
Revenue failed to meet consensus expectations and the company forecast flat Ebitda margins growth for the new year.
